Related Experiment Video
Updated: May 21, 2026
08:10
An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019
Fenofibrate - a potential systemic treatment for diabetic retinopathy?
Tien Yin Wong1, Rafael Simó, Paul Mitchell
1Singapore Eye Research Institute, National University of Singapore, Singapore. tien_yin_wong@nuhs.edu.sg
American Journal of Ophthalmology
|June 20, 2012
Summary
Fenofibrate shows promise in treating early diabetic retinopathy by reducing the need for laser treatment and slowing disease progression in patients with type 2 diabetes. Further research into its mechanisms can optimize its use.
Area of Science:
- Ophthalmology
- Endocrinology
- Pharmacology
Background:
- Diabetic retinopathy is a leading cause of vision loss in patients with diabetes.
- Systemic treatments are being explored to manage diabetic retinopathy progression.
- Fenofibrate, a lipid-lowering agent, has demonstrated potential therapeutic effects.
Purpose of the Study:
- To evaluate fenofibrate as a systemic treatment for diabetic retinopathy.
- To review clinical and experimental data on fenofibrate's efficacy and mechanisms.
Main Methods:
- Review of two major randomized controlled trials: FIELD and ACCORD-Eye.
- Analysis of progression criteria including laser treatment and Early Treatment Diabetic Retinopathy Study (ETDRS) scale changes.
- Inclusion of experimental studies on fenofibrate's mode of action.
Main Results:
- Fenofibrate use in 11,388 patients with type 2 diabetes showed a 31% reduction in first laser treatment.
- Significant slowing of diabetic retinopathy progression over 4-5 years (5.0% and 3.7% absolute reductions).
- Beneficial effects observed in lipid and non-lipid pathways, including anti-apoptosis, antioxidant, anti-inflammatory, and neuroprotective actions.
Conclusions:
- Robust clinical data support fenofibrate as an adjunctive treatment for early diabetic retinopathy in type 2 diabetes.
- Risk-benefit assessment is crucial for therapy initiation.
- Further research into fenofibrate's mode of action is needed to optimize its clinical application.
Related Concept Videos
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
01:28Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:22Diabetic Neuropathy
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
01:31Diabetic Foot Ulcer
Definition A diabetic foot ulcer (DFU) is a chronic, non-healing wound that develops in individuals with diabetes. It typically occurs on pressure-bearing areas such as the heel, metatarsal heads, or hallux, and carries a high risk of infection and amputation.Pathophysiology • The development of DFUs can be explained by four interconnected mechanisms: neuropathy, ischemia, infection, and impaired wound healing. • Neuropathy is the most common factor. Sensory neuropathy reduces pain perception,...